Variables associated with human papillomavirus (HPV) vaccine acceptance by men

Journal of the American Board of Family Medicine

Volumn 22, Issue 1, 2009, Pages 34-42

  Ferris, Daron G ^a,b   Waller, Jennifer L ^c   Miller, Jeremiah ^b   Patel, Pratik ^b   Price, George A ^c   Jackson, Lanier ^b   Wilson, Courtesia ^d  

^a Gynecologic Cancer Prevention Center   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Department of Biostatistics ^*  (United States)

^d PAINE COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; DRUG SAFETY; EDUCATION; ETHNICITY; HISPANIC; HUMAN; MALE; SEATBELT; SEXUALITY; TOBACCO;

ADOLESCENT; ADULT; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; RISK FACTORS; SEX FACTORS; STATISTICS AS TOPIC; VACCINATION; YOUNG ADULT;

EID: 58549100913     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2009.01.080008     Document Type: Article

References (23)

1. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-78.
2. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. N Engl J Med 2007;356:1915-27.
3. The FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ. A combined analysis of four randomized clinical trials. Lancet 2007;369:1861-8.
4. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
5. Nielson CM, Flores R, Harris RB, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 2007;16:1107-14.
6. Wiatrak BJ, Wiatrak DW, Broker TR, Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 2004;114:1-23.
7. Maloney EM, Unger ER, Tucker RA, et al. Longitudinal measures of human papillomavirus 6 and 11 viral loads and antibody response in children with recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2006;132:711-5.
8. Abramowitz L, Benabderrahmane D, Ravaud P, et al. Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. AIDS 2007;21:1457-65.
9. Cupp MR, Malek RS, Goellner JR, Smith TF, Espy MJ. The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol 1995;154:1024-9.
10. Gregoire L, Cubilla AL, Reuter VE, Hass GP, Lancaster WD. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst 1995;87:1705-9.
11. Malek RS, Goellner JR, Smith TF, Espy MJ, Cupp MR. Human papillomavirus infection and intraepithelial, in situ, and invasive carcinoma of the penis. Urol 1993;42:159-70.
12. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intraepithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998;12:495-503.
13. Frish M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997;337:1350-8.
14. Syrjanen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005;32:S59-66.
15. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
16. Ferris DG, Waller JL, Owen A, Smith J. HPV vaccine acceptance among mid-adult women. J Am Bd Fam Med 2008;21:31-7.
17. Ferris DG, Waller JL, Owen A, Smith J. Mid adult women's attitudes about receiving the prophylactic human papillomavirus vaccine. J Lower Genital Tract Dis 2007;11:166-72.
18. Ferris DG, Waller JL, Miller J, et al. Men's attitudes toward receiving the HPV vaccine. J Lower Genital Tract Dis 2008;12:276-81.
19. Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006;194:1044-57.
20. Wiley DJ, Wiesmeier E, Masongsong E, et al. Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection. Cancer Epidemiol Biomarkers Prev 2006;15:915-20.
21. McIntyre-Seltman K, Castle PE, Guido R, Schiffman M, Wheeler CM, ALTS Group. Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. Cancer Epidemiol Biomarkers Prev 2005;14:1165-70.
22. Ferris DG, Hainer BL, Pfenninger JL, Zuber TJ. See and treat electrosurgical loop excision of the cervical transformation zone. J Fam Pract 1996;42:253-7.
23. Davis K, Dickman ED, Ferris DG, Dias JK. Human papillomavirus vaccine acceptability among parents of 10 to 15 year old adolescents. J Low Genit Tract Dis 2004;8:188-94.